Turning Point Therapeutics, Inc.
Clinical trials sponsored by Turning Point Therapeutics, Inc., explained in plain language.
A precision oncology company developing targeted therapies for cancer, acquired by Bristol-Myers Squibb.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for kids with rare cancers: targeted drug repotrectinib enters trial
Disease control Recruiting nowThis study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC